Selective neuromuscular blocks and chemoneurolysis in the localized treatment of spasticity

Europa Medicophysica

Volumn 40, Issue 2, 2004, Pages 123-130

  Carda, S ^a   Molteni, F ^a  

^a VALDUCE HOSPITAL   (Italy)

Author keywords

Botulinum toxins; Chemoneurolysis; Neuromuscular blockade

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PHENOL;

CHEMONEUROLYSIS; DIPLOPIA; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPHAGIA; HUMAN; MAXIMUM PERMISSIBLE DOSE; MULTIPLE SCLEROSIS; MUSCLE CONTRACTION; MUSCLE HYPERTONIA; MUSCLE TONE; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; STRABISMUS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 2942715365     PISSN: 00142573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Van Ermengem E. Ueber einen neuen anaerobien Bacillus und seine Beziehungen zum Botulismus. Zeitschrift fur Hygiene und Infektionskrankheiten 1897;26:1-56.
2. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on neuromuscular junction. J Physiol 1949;109:10-24.
3. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1995;45:712-7.
4. Jankovic J, Brin M, Comella C. Handbook of botulinum toxin treatment for cervical dystonia. New York: Churchill Livingstone; 1994.
5. Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
6. Jankovic J, Hallett M. Therapy with botulinum toxin. New York: Marcel Dekker; 1994.
7. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for the treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-6.
8. Pasricha PJ, Ravic WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalsia. N Engl J Med 1995;332:774-8.
9. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1990;40:1213-8.
10. Hesse S, Lucke D, Malezic M, Bertelt C, Friedrich H. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4.
11. Trosh RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994;9:601-9.
12. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1995;10:686-7.
13. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
14. Huttner WB. Snappy exocytoxins. Nature 1993;365:104-5.
15. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophtalmol 1991;109:393-5.
16. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophtalmol 1987;105:1703-11.
17. Alderson K, Holds JB, Anderson RL. Botulinum induced alteration of nerve muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991;41:1800-5.
18. Black JD, Dolly JO. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 1987;23:767-79.
19. Williams RS, Tse CK, Dolly JO, Hambleton P, Melling J. Radio-iodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur J Biochem 1983;131:437-45.
20. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-83.
21. Ludlow CL, Hallett M, Rhew K, Cole R, Shimizu T, Sakaguchi G et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992; 326:349-50.
22. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM et al. Botulinum toxin type B (BotB): a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
23. Durif D. Clinical bioequivalence of the current commercial preparations of Botulinum toxin. Fur J Neurol 1995;2:17-8.
24. Odergren T, Hjaltason H, Kakkola S, Solders G, Hanko J, Fehling C et al. A double blind randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64:6-12.
25. Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, Suh YL et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-6.
26. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9: 213-7.
27. Zuber M, Sebald M, Bathien N, Derecondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-8.
28. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
29. Awaad Y, Tayem H. High dose of botulinum toxin type-a (Btx); Safety and efficacy in patients with cerebral palsy. Eastern Mediterranean Cerebral Palsy and Development Medicine Congress. 15-17th april, 2002 Istanbul, Turkey.
30. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003;84:103-7.
31. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophtalmology 1979;87:1044-9.
32. Jankovic J, Schwartz K. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-6.
33. Gormley ME, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve 1997;20(Suppl 6):S14-S20.
34. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve 1997;20 (Suppl 6):S21-S35.
35. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997;12:89-94.
36. Rodriquez AA, McGinn M, Chappell R. Botulinum toxin injection of spastic finger flexors in hemiplegic patients. Am J Phys Med Rehabil 2000;79:44-7.
37. Hesse S, Werner C, Bardeleben A, Brandl-Hesse B. Management of upper and lower limb spasticity in neuro-rehabilitation. Acta Neurochir Suppl 2002;79:117-22.
38. Albany K. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Muscle Nerve 1997;20(Suppl 6):S221-31.
39. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F et al. Use of botulinum toxin type A in management of adult spasticity. A European consensus statement. J Rehabil Med 2003;35:1-2.
40. Pierson SH, Katz DI, Tarsy D. Botulinum A toxin in the treatment of spasticity: functional implication and patient selection. Arch Phys Med Rehab 1996;77:717-21.
41. Sampaio C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Caldos A. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997;11:3-7.
42. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5.
43. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM et al. Botulinum toxyn type A in the treatment of upper extremity spasticity: a randomized, double blind, placebo controlled trial. Neurology 1996;46:1306-10.
44. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347: 395-400.
45. Woldag H, Hummelsheim H. Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 2003;50:165-71.
46. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84.
47. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28:512-5.
48. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open labeled trial. Neurology 1996;47: 939-44.
49. Wilson DJ, Childers MK, Cooke DL, Smith BK. Kinematic changes following botulinum toxin injection after traumatic brain injury. Brain Inj 1997;11:157-67.
50. Richardson D, Edwards S, Sheean G, Greenwood RJ, Thompson AJ. The effect of botulinum toxin on hand function after incomplete spinal cord injury at level of C5/C6: a case report. Clin Rehabil 1997; 11:288-92.
51. Al-Khodairy AT, Gobelet C, Rossier AB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients? Spinal Cord 1998;36:854-8.
52. Fried GW, Fried KM. Spinal cord injury and use of botulinum toxin in reducing spasticity. Phys Med Rehabil Clin N Am 2003;14: 901-10.
53. Khalili AA, Betts HB. Peripheral nerve block with phenol in the management of spasticity. JAMA 1967;200:1155-7.
54. Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil 1996;10:40-3.
55. Felsenthal G. Nerve blocks in the lower extremities: anatomic considerations. Arch Phys Med Rehabil 1974;55:504-7.
56. Keenan MA, Tomas ES, Stone L, Gersten LM. Percutaneous phenol block of the muscolocutaneous nerve to control elbow flexor spasticity. J Hand Surg 1990;2:340-6.
57. Felsenthal G. Nerve blocks in the lower extremities: anatomic considerations. Arch Phys Med Rehabil 1974;55:504-7.
58. Ofluoglu D, Esquenazi A, Hirai B. Temporospatial parameters of gait after obturator neurolysis in patients with spasticity. Am J Phys Med Rehabil 2003;82:832-6.